Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.82

1.67 (2.16%)

, TEVA

Teva

$23.80

0.04 (0.17%)

10:22
07/12/18
07/12
10:22
07/12/18
10:22

Novartis prevails in Gilenya patent challenge brought by Teva and Apotex

The U.S. Patent and Trademark Office's Patent Trial and Appeal Board wrote that petitioners Apotex, Teva (TEVA) and Sun Pharmaceutical failed to show, by a preponderance of the evidence, that claims 1-6 of U.S. Patent No. US 9,187,405 held by Novartis (NVS) related to its Gilenya are unpatentable, according to a decision dated July 11 that was posted to the USPTO site.

NVS

Novartis

$78.82

1.67 (2.16%)

TEVA

Teva

$23.80

0.04 (0.17%)

  • 10

    Sep

  • 16

    Sep

NVS Novartis
$78.82

1.67 (2.16%)

07/02/18
RILY
07/02/18
NO CHANGE
Target $7.5
RILY
Buy
Adamis price target raised to $7.50 from $6.25 at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva raised his price target for Adamis Pharmaceuticals (ADMP) to $7.50 after the company entered into a strategic partnership with Novartis (NVS) unit Sandoz. The analyst views the agreement as favorable and keeps a Buy rating on Adamis.
07/02/18
HCWC
07/02/18
NO CHANGE
Target $10
HCWC
Buy
Adamis price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert raised his price target for Adamis Pharmaceuticals (ADMP) to $10 after the company announced that Novartis (NVS) division Sandoz division will commercialize Symjepi. While the deal took longer than expected, the terms of a 50:50 split is better than anticipated, Kolbert tells investors in a research note. The analyst sees Sandoz as a "great partner" and reiterates a Buy rating on Adamis.
07/02/18
ROTH
07/02/18
NO CHANGE
Target $22
ROTH
Buy
Cryoport price target raised to $22 from $12.50 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Cryoport (CYRX) to $22 from $12.50 while reiterating a Buy rating on the shares. The analyst notes that the European Medicines Agency recommended "marketing authorizations" for therapies developed by two of Cryoport's clients, Gilead's (GILD) Yescarta and Novartis' (NVS) Kymriah. Baldry believes these two approvals roughly double the addressable market for the therapies and offer upside potential to our 2019 forecasts.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
TEVA Teva
$23.80

0.04 (0.17%)

06/18/18
06/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Francesca's (FRAN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she has increased confidence in the company's turnaround following meetings with management. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying Chevron offers relatively more leverage than most peers to higher oil prices, which should reach cyclical highs over the next 6 to 12 months, while low WTI exposure maximizes earnings and free cash flow generation. 3. Trovagene (TROV) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. 4. RBS (RBS) upgraded to Buy from Hold at Investec. 5. Teva (TEVA) upgraded to Market Perform from Underperform at Wells Fargo with analyst David Maris citing a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/25/18
GSCO
06/25/18
NO CHANGE
Target $28
GSCO
Buy
Teva price target raised to $28 from $25 at Goldman Sachs
Goldman analyst Jami Rubin raised Buy rated Teva's price target to $28 from $25 following meetings with management last week. The analyst said there has been a "stark shift" by interim management from being fairly reactionary and directionless to now being a company led by leaders who are "action-oriented" with a rapid and clear path to recovery. Rubin said the discussions focused on progress on price cuts, deleveraging, stabilization of the US generics business, specialty opportunities, and the next chapter of growth expected in 2020. The analyst believes guidance is likely to be revised higher as Copaxone has show to be more durable despite generic competition and US generics have stabilized and guidance still assumes ProAir competition this year. Further, Rubin sees upside potential from Austedo and Fremanezumab that could drive EBITDA upside and cash flow for faster debt repayment.
06/27/18
SBSH
06/27/18
NO CHANGE
SBSH
Buy
Teva added to CIti's US Focus List with 'favorable' risk-reward profile
Citi analyst Liav Abraham added Teva to his US Focus List, telling investors in a research note that he continues to see a "favorable" risk-reward profile and that the stock benefits from the most clear and material upside to estimates among the stocks in his coverage universe. He views earnings upside as the most material driver of stock price performance for the specialty pharma sector over the near to medium term, "especially against a backdrop of fundamentals that appear to have stabilized." Looking ahead, Abraham sees a guidance raise along with Q2 earnings.
07/12/18
GSCO
07/12/18
DOWNGRADE
Target $74
GSCO
Sell
Perrigo downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jami Rubin downgraded Perrigo (PRGO) to Sell and lowered her price target for the shares to $74 from $78. The analyst sees "no meaningful risk" to estimates but expects the "business to drift" due to a lack of meaningful new launches in the pipeline. The market may also attribute a lower multiple to Perrigo's consumer business as rates rise, which creates downside risk to the equity, Rubin tells investors in a research note. She sees more upside in other stocks, namely Mylan (MYL) and Teva (TEVA).

TODAY'S FREE FLY STORIES

ZTCOY

ZTE Corp.

$0.00

(0.00%)

14:24
07/20/18
07/20
14:24
07/20/18
14:24
Hot Stocks
Sen. Schumer: Trump's backtrack on ZTE example of 'being weak' »

Top Senate Democrat Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

ZTCOY

ZTE Corp.

$0.00

(0.00%)

14:21
07/20/18
07/20
14:21
07/20/18
14:21
Periodicals
Lawmakers remove anti-ZTE measure from defense bill, Reuters says »

Top Senate Democrat Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/20/18
07/20
14:17
07/20/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/20/18
07/20
14:16
07/20/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RS

Reliance Steel

$91.30

0.24 (0.26%)

14:10
07/20/18
07/20
14:10
07/20/18
14:10
Options
Call buyers in Reliant Steel ahead of earnings next week »

Call buyers in Reliant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$280.04

0.09 (0.03%)

14:08
07/20/18
07/20
14:08
07/20/18
14:08
General news
Trump worried Fed will hike rates twice this year, CNBC reports 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$280.04

0.09 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
07/20/18
07/20
14:05
07/20/18
14:05
General news
Action Economics Survey results: »

Action Economics Survey…

SWN

Southwestern Energy

$5.36

-0.005 (-0.09%)

13:55
07/20/18
07/20
13:55
07/20/18
13:55
Options
Southwestern Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

13:55
07/20/18
07/20
13:55
07/20/18
13:55
General news
Treasury Curve Action: longer yields led to steepening »

Treasury Curve Action:…

LHO

LaSalle Hotel

$35.10

0.11 (0.31%)

, PEB

Pebblebrook Hotel

$39.66

-0.06 (-0.15%)

13:47
07/20/18
07/20
13:47
07/20/18
13:47
Hot Stocks
LaSalle Hotel confirms receipt of letter from Pebblebrook Hotel »

LaSalle Hotel Properties…

LHO

LaSalle Hotel

$35.10

0.11 (0.31%)

PEB

Pebblebrook Hotel

$39.66

-0.06 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ARDX

Ardelyx

$4.40

-0.05 (-1.12%)

13:42
07/20/18
07/20
13:42
07/20/18
13:42
Hot Stocks
Breaking Hot Stocks news story on Ardelyx »

Adage Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$55.30

-4.1 (-6.90%)

13:42
07/20/18
07/20
13:42
07/20/18
13:42
Recommendations
Lumentum analyst commentary  »

Lumentum should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$64.01

-0.49 (-0.76%)

13:40
07/20/18
07/20
13:40
07/20/18
13:40
Options
Hess sees aggressive call buying ahead of earnings next week »

Hess sees aggressive call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FFIV

F5 Networks

$172.71

1.06 (0.62%)

, S

Sprint

$5.46

-0.015 (-0.27%)

13:39
07/20/18
07/20
13:39
07/20/18
13:39
Hot Stocks
F5 Networks names Sprint CEO Michel Combes to board »

F5 Networks (FFIV)…

FFIV

F5 Networks

$172.71

1.06 (0.62%)

S

Sprint

$5.46

-0.015 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 01

    Aug

  • 08

    Aug

  • 09

    Aug

LGF.A

Lionsgate

$24.92

-0.04 (-0.16%)

, LGF.B

Lionsgate

$23.91

-0.06 (-0.25%)

13:37
07/20/18
07/20
13:37
07/20/18
13:37
Periodicals
Ex-Lions Gate general counsel was mired in legal drama prior to exit, WSJ says »

Lions Gate general…

LGF.A

Lionsgate

$24.92

-0.04 (-0.16%)

LGF.B

Lionsgate

$23.91

-0.06 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

UNIT

Uniti Group

$17.85

-0.785 (-4.21%)

13:35
07/20/18
07/20
13:35
07/20/18
13:35
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

LITE

Lumentum

$55.30

-4.1 (-6.90%)

13:33
07/20/18
07/20
13:33
07/20/18
13:33
Recommendations
Lumentum analyst commentary  »

Lumentum selloff today a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$280.19

0.24 (0.09%)

, IWM

iShares Trust Russell 2000 Index Fund

$169.13

-0.01 (-0.01%)

13:30
07/20/18
07/20
13:30
07/20/18
13:30
Technical Analysis
On The Fly: ETF fund flow highlights »

For the past week, there…

SPY

SPDR S&P 500 ETF Trust

$280.19

0.24 (0.09%)

IWM

iShares Trust Russell 2000 Index Fund

$169.13

-0.01 (-0.01%)

QQQ

Invesco QQQ Trust

$179.51

0.48 (0.27%)

BBJP

JPMorgan BetaBuilders Japan ETF

$24.08

0.065 (0.27%)

XLF

Financial Select Sector

$27.59

0.085 (0.31%)

XLI

Industrial Select Sector SPDR

$74.65

0.12 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$194.73

2.71 (1.41%)

13:24
07/20/18
07/20
13:24
07/20/18
13:24
Hot Stocks
Canadian Pacific, TCRC-T&E ratify four-year agreement »

Canadian Pacific Railway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,821.64

8.79 (0.48%)

13:17
07/20/18
07/20
13:17
07/20/18
13:17
Hot Stocks
Amazon announces new fulfillment center in Spokane »

Amazon.com announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/20/18
07/20
13:17
07/20/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/20/18
07/20
13:16
07/20/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESL

Esterline

$81.10

5.6 (7.42%)

13:11
07/20/18
07/20
13:11
07/20/18
13:11
Periodicals
Esterline in early stages of exploring sale, WSJ reports »

Esterline Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

SN

Sanchez Energy

$4.72

-0.1 (-2.07%)

13:10
07/20/18
07/20
13:10
07/20/18
13:10
Options
Sizable put spreads in Sanchez Energy as a bullish play is extended »

Sizable put spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

PH

Parker-Hannifin

$164.52

-0.61 (-0.37%)

, TXT

Textron

$67.34

0.34 (0.51%)

13:08
07/20/18
07/20
13:08
07/20/18
13:08
Hot Stocks
Parker Aerospace wins Cessna Denali contract for bleed air control system »

Parker Aerospace, a…

PH

Parker-Hannifin

$164.52

-0.61 (-0.37%)

TXT

Textron

$67.34

0.34 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.